[HTML][HTML] Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
S Contreras-Castillo, A Plaza, J Stojanova… - Frontiers in …, 2021 - frontiersin.org
Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms …
[HTML][HTML] The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
I Lunde, S Bremer, K Midtvedt, B Mohebi… - European journal of …, 2014 - Springer
Abstract Purpose Tacrolimus (Tac) and cyclosporine (CsA) are mainly metabolized by
CYP3A4 and CYP3A5. Several studies have demonstrated an association between the …
CYP3A4 and CYP3A5. Several studies have demonstrated an association between the …
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant …
V Haufroid, M Mourad, V Van Kerckhove… - Pharmacogenetics …, 2004 - journals.lww.com
Cyclosporine and tacrolimus are immunosuppressive drugs largely used in renal
transplantation. They are characterized by a wide inter-individual variability in their …
transplantation. They are characterized by a wide inter-individual variability in their …
[PDF][PDF] Impact of CYP3A4* 1B and CYP3A5* 3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients
D ŻochowskaABCDEF, J WyzgałCDF… - Ann …, 2012 - ppm.wum.edu.pl
Summary Background: Calcineurin inhibitor (cyclosporine, CsA) and mTOR inhibitors
(sirolimus, SRL)–immunosuppressants used to prevent allograft rejection after renal …
(sirolimus, SRL)–immunosuppressants used to prevent allograft rejection after renal …
Effect of CYP3A4* 22, CYP3A5* 3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation
D Moes, JJ Swen, J Den Hartigh… - CPT …, 2014 - Wiley Online Library
Cyclosporine, everolimus, and tacrolimus are the cornerstone of immunosuppressive
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …
therapy in renal transplantation. These drugs are characterized by narrow therapeutic …
Switching immunosuppression from cyclosporine to tacrolimus in kidney transplant recipients based on CYP3A5 genotyping
X Wang, Y Yang, Z Liu, C Xiao, L Gao… - Therapeutic Drug …, 2019 - journals.lww.com
Background: Kidney transplant recipients on long-term cyclosporine (CsA) therapy may
develop multiple adverse drug events, and immunosuppression conversion from CsA to …
develop multiple adverse drug events, and immunosuppression conversion from CsA to …
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
JN Roy, A Barama, C Poirier, B Vinet… - Pharmacogenetics and …, 2006 - journals.lww.com
Objective The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …
CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation
J Wang - Expert review of molecular diagnostics, 2009 - Taylor & Francis
Most immunosuppressive drugs have a narrow therapeutic index and large interpatient
variabilities in their pharmacokinetic and pharmacodynamic profiles. Identification of …
variabilities in their pharmacokinetic and pharmacodynamic profiles. Identification of …
Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus
Y Zhao, DL Guan, MS Song, J Liu, G Fu - Transplantation, 2004 - journals.lww.com
Aims: The calcineurin inhibitors cyclosporine and tacrolimus are the major
immunosuppressive agents, It becomes complicated to use them for their interindividual …
immunosuppressive agents, It becomes complicated to use them for their interindividual …
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
L Chen, GVR Prasad - Pharmacogenomics and personalized …, 2018 - Taylor & Francis
Tacrolimus is a commonly used immunosuppressant after kidney transplantation. It has a
narrow therapeutic range and demonstrates wide interindividual variability in …
narrow therapeutic range and demonstrates wide interindividual variability in …